Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence by Deborah, Fenlon
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
Patient Preference and Adherence
                                             
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa38784
_____________________________________________________________
 
Paper:
Brett, J., Boulton, M., Fenlon, D., Hulbert-Williams, N., Walter, F., Donnelly, P., Lavery, B., Morgan, A., Morris, C. et.
al. (2018).  Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence.
Patient Preference and Adherence, 12, 291-300.
http://dx.doi.org/https://doi.org/10.2147/PPA.S145784
 
 
 
 
 
 
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/ 
 AUTH
OR
PROO
F 
COPY
 
Not fo
r 
public
ation
© 2018 Brett et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Patient Preference and Adherence 2018:12 1–10
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
1
O r i g i n A l  r e s e A r c h
open access to scientific and medical research
Open Access Full Text Article
145784  18 December 2017
Adjuvant endocrine therapy after breast cancer: 
a qualitative study of factors associated with 
adherence
Jo Brett1
Mary Boulton1
Debbie Fenlon2
nick J hulbert-Williams3
Fiona M Walter4
Peter Donnelly5
Bernadette lavery6
Adrienne Morgan7
carolyn Morris7
eila Watson1
1Faculty of health and life sciences, 
Oxford Brookes University, Oxford, 
2college of human and health 
sciences, swansea University, swansea, 
Wales, 3Department of Psychology, 
chester research Unit for the 
Psychology of health, University 
of chester, chester, 4Department 
of Public health and Primary care, 
University of cambridge, cambridge, 
5south Devon healthcare nhs 
Foundation Trust, Torbay hospital, 
Torquay, 6cancer services, Oxford 
University hospitals Foundation nhs 
Trust, Oxford, 7independent cancer 
Patients’ Voice, london, UK
Introduction: Despite evidence of the efficacy of adjuvant endocrine therapy (AET) in 
reducing the risk of recurrence and mortality after treatment for primary breast cancer, adher-
ence to AET is suboptimal. This study aimed to explore factors that influence adherence 
and nonadherence to AET following breast cancer to inform the development of supportive 
interventions.
Methods: Interviews were conducted with 32 women who had been prescribed AET, 2–4 years 
following their diagnosis of breast cancer. Both adherers (n=19) and nonadherers (n=13) were 
recruited. The analysis was conducted using the Framework approach.
Results: Factors associated with adherence were as follows: managing side effects including 
information and advice on side effects and taking control of side effects, supportive relation-
ships, and personal influences. Factors associated with nonadherence were as follows: burden 
of side effects, feeling unsupported, concerns about long-term AET use, regaining normality, 
including valuing the quality of life over length of life, and risk perception.
Conclusion: Provision of timely information to prepare women for the potential side effects 
of AET and education on medication management strategies are needed, including provision 
of timely and accurate information on the efficacy of AET in reducing breast cancer recurrence 
and on potential side effects and ways to manage these should they arise. Trust in the doctor–
patient relationship and clear patient pathways for bothersome side effects and concerns with 
AET are important. Training and education on AET for GPs should be considered alongside 
novel care pathways such as primary care nurse cancer care review and community pharmacist 
follow-up.
Keywords: hormone therapy, oncology, patient experiences, support, follow-up
Introduction
Breast cancer is the most common cancer among women worldwide.1 Approximately 
55,000 women in the UK are diagnosed every year, and one in five of them experi-
ence a recurrence at some point following primary treatment.2,3 Adjuvant endocrine 
therapies (AETs) such as tamoxifen and aromatase inhibitors (AIs) have proven 
clinical benefit, reducing the risk of recurrence for women with estrogen receptor-
positive breast cancer by 11.8% and mortality by 9.2% over 5 years.4 Guidelines until 
recently recommended 5 years of treatment, but following trial evidence, this is being 
extended to 10 years.5–9
Despite the known efficacy of AET,5–9 adherence to AET is suboptimal. In a 
systematic review of 29 studies, adherence to AET over 5 years ranged from 41 to 
72%.10 Previous studies have reported that ,50% of women complete a full 5 years 
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of AET, leading to increased recurrence and a 20% rise in 
breast cancer mortality, as well as higher medical costs and 
poorer quality of life.11–13 As the time to discharge from 
routine follow-up decreases and the recommended time to 
take AET increases to 10 years, adherence rates could be 
expected to fall further.
While previous quantitative studies have identified factors 
associated with nonadherence to AET, including side effects, 
lack of knowledge about AET, and medication beliefs,14–16 
only limited qualitative research has been conducted in this 
area.17,18 In order to develop patient-centered interventions 
and guide clinical practice to improve medication adherence, 
a thorough understanding of women’s perspectives on this 
topic is essential.19
Using interviews with women, this study aimed to 
explore, in depth, the factors that influence whether women 
adhere to or do not adhere to AET to inform the develop-
ment of interventions to improve adherence and ultimately 
to improve outcomes for women who have been treated for 
breast cancer.
Methods
A sample of women who had been prescribed AET following 
treatment for breast cancer were recruited 2–4 years after 
initiating the treatment. The sample included both adherers 
and nonadherers:
•	 Adherers were defined as still taking the medication as 
recommended.
•	 Nonadherers were defined as having initiated AET but 
now had stopped taking the medication.
Participants were identified and recruited through two 
sources. Initially, women who had taken part in a previous 
questionnaire survey (n=292) and reported adherence or 
nonadherence to AET were asked whether they would 
participate in an interview.14 As the number of nonadherers 
recruited from this source was small (n=5), a second group 
of women who self-reported nonadherence to AET was 
recruited through 1 month advertisements on the follow-
ing two UK charity website forums: Independent Cancer 
Patients’ Voice and Breast Cancer Care (n=8).
Semistructured interviews were conducted by JB either 
at the woman’s home or at another place of her choice. 
Interviews lasted between 41 and 103 minutes (mean 
60 minutes). All interviews were digitally recorded and 
transcribed verbatim.
Analysis was carried out using the Framework approach 
with adherers and nonadherers analysed as two separate 
groups.20 JB read all the transcripts, and both MB and EW 
read a selection of the same transcripts in order to gain an 
overview of the women’s accounts and identify recurring 
themes. This led to the development of a coding framework. 
Two transcripts from each group were coded by at least 
two of the authors. Coded transcripts were compared and 
codes further refined and then grouped together into broader 
categories. The Framework approach allows both inductive 
and deductive analyses.20 Codes and categories were there-
fore derived both inductively from the women’s accounts 
and deductively from relevant literature, for example, the 
necessity-concerns framework developed by Horne et al.21,22
The coding framework was then applied to index the 
transcripts, that is, a code was attached to each relevant 
passage of text using the software NVivo 10. JB coded all 
interviews, and MB coded one from each group to assess 
consistency. When indexing was complete, a matrix was cre-
ated, with a page for each category and one code per column 
and one participant per row. For each participant, data were 
abstracted for each code and summarized in the appropriate 
cell on the matrix, with notes of supporting quotes. The 
matrix was then reviewed in relation to the research ques-
tions and themes generated by making comparisons and 
looking for connections across cells, both within and between 
participants. Interpretation of the data is reported here using 
relevant quotes to illustrate.
ethics
Ethics approval was obtained for this study from the UK 
National Health Service National Research Ethics Service 
(NHS NRES: 09/H050501/44) and from the Oxford Brookes 
University Research Ethics Committee (UREC: 140832). 
In accordance with ethics regulations, consent was obtained 
from all patients to participate in the study.
Results
Interviews were conducted with 32 women, all of whom 
had been prescribed AET after treatment for primary breast 
cancer. Participants include 19 adherers and 13 nonadherers 
from England and Wales. Characteristics of the sample are 
listed in Table 1.
For those who continued to take their medication, three 
key themes which facilitated adherence were identified. For 
those who had discontinued their medication, five key themes 
associated with nonadherence were identified.
Factors associated with adherence to AeT
Managing side effects
information and advice
Receiving timely information and expert advice were impor-
tant to participants. Adherers valued timely and relevant 
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information that they sought from a range of sources 
including health professionals, the Internet, and other women 
taking AET. Many would have liked more information in 
relation to side effects than they received:
I would have liked more information to prepare for the 
side effects. I was given lots of information about the side 
effects of chemotherapy and how to manage them, but 
I wasn’t expecting the side effects of AET. So perhaps that 
made it worse. [P1 adherer]
For some adherers, the source of information was also 
important and advice provided by a trusted doctor was par-
ticularly valued in guiding their behavior:
I wanted to know more about why I was taking it and he 
went into a lot of detail of how it works. [If my doctor says] 
it reduces the risk of the cancer coming back, I’d be mad 
not to take it. [P19 adherer]
I must admit I take it – if they [doctors] say it’s a good 
idea I’m very much […] I think because my experience has 
been so positive with them [doctors] I’ve not come away 
doubting anything. [P2 adherer]
For others, lack of timely information had meant delay 
in attributing the side effects to AET lead to anxiety and 
concern about other conditions:
I thought it was the long-term effects of chemotherapy, 
so I thought it would improve. When it didn’t long-term, 
I began to realise it was possibly the hormone therapy. 
[P17 adherer]
Taking control
Adherers seemed motivated to manage the side effects 
caused by AET and to take control over their bodies again. 
Some had sought information from the Internet or online 
forums on ways to adapt their lifestyle to help them tolerate 
their medication, such as changing their diet, increasing 
the exercise they took, and decreasing their alcohol and 
caffeine intake, and also on coping strategies that helped 
alleviate side effects such as using “chill” pillows, drinking 
ice water, and wearing thin layers of clothes.
I read on the internet about looking after myself […] 
I eat much healthier now, and avoid alcohol and caffeine. 
A bit boring, but it helps. The side effects are less now. 
[P7 adherer]
The online forum had other women chatting about 
it […] the ‘chill’ pillows are great at night – I bought it 
online. [P1 adherer]
I wanted to be able to do something for myself. I wanted 
to be able to adapt and have some way of coping with the 
side effects. I started by eating more healthily. It was a way 
of taking back control. [P5 adherer]
supportive relationships
Adherers found supportive relationships from family and 
health professionals valuable in motivating them in continued 
use of AETs. Some spoke about supportive husbands, family, 
or friends and how their support enabled them to carry on:
He [husband] is brilliant. He’s very understanding – he 
has been with me 100% through everything. He has gone 
to hospital appointments with me but he just worries about 
how I feel. [P6 adherer]
Others described a positive and supportive relationship 
with their surgeon, oncologist, or GP, whose care and concern 
encouraged continuation with the medication:
I had a long conversation with him [GP] about it – he 
really cared. He swapped me on to this one – I know he is 
doing what he can. If you feel someone cares, it kind of 
encourages you to keep going, if you know what I mean. 
[P18 adherer]
Personal influences
Several adherers spoke about their responsibility toward 
others as important in their decision to continue taking AET. 
Adherers who had young children at home spoke about their 
Table 1 characteristics of sample
Adherers 
(n=19)
Non-adherers 
(n=13)
recruitment method
Questionnaire survey
UK charity forums
19
0
5
8
Age (years)
range
Median
37–77
59
53–76
64
Marital status, n (%)
Married
single
separated
Widow
15 (79)
1 (5)
–
3 (16)
10 (77)
2 (15)
1 (8)
–
education, n (%)
“ ‘O’ O” level, gcse, or equivalent
“ ‘A’ A” level or equivalent
college or university degree,
hnD or hnc
Postgraduate qualification
1 (5)
–
16 (84)
–
2 (11)
–
–
9 (69)
–
4 (31)
Type of AeT, n (%)
Tamoxifen
Aromatase inhibitor
swapped 
13 (68)
3 (16)
3 (16)
6 (46)
1 (6)
6 (46)
Abbreviation: AeT, adjuvant endocrine therapy.
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adherence to AET in terms of their commitment to their 
children and their need to stay alive and healthy for their 
sake, whatever the cost to themselves.
I will carry on despite how I feel just because it’s the only 
thing I can do and I’ll do anything I can because of the kids 
really – I do want to be around [for them]. [P1, adherer]
Similarly, another woman continued taking her medica-
tion for the sake of her husband whose first wife had died 
of breast cancer, despite the weight gain she experienced 
and its impact on her confidence to continue working as a 
health advisor:
I really didn’t want to take it [because of weight gain] and 
I have to say the only reason I have taken it, I think, it’s 
because of my husband. Because e lost his first wife to 
breast cancer and I think I would be really selfish if I didn’t 
take it for him but if it had been me I might not have taken 
it. [P6 adherer]
For some women, it was their previous experience of 
loss to cancer that influenced their decision. Some adherers 
had experienced the loss of loved ones from cancer, and this 
experience provided the motivation to continue with their 
medication. They perceived AET as a potentially life-saving 
“safety net” and were more likely to want to continue for 
10 years. In the following examples, one woman had lost 
her mother after breast cancer recurred when she stopped 
taking tamoxifen, while the other woman had lost both her 
husband and colleague to cancer:
[…] [my mother’s] trouble started up again when she 
stopped the tamoxifen so I have got that double idea that 
I’m safe while I’m on it. [P12 adherer]
My husband died of cancer in 2002 […] Then in 
2006 […] my colleague died and I was diagnosed in 2010. 
So that was just four years, so you do think ‘Oh my god, 
that’s your death sentence’[…] you just want to take it for 
as long as possible [P8 adherer]
Factors associated with nonadherence to AeT
The burden of side effects
There was considerable heterogeneity in side effects described 
by nonadherers, and nonadherers tended to perceive them-
selves as suffering more from the severity and impact of 
side effects on their daily life than adherers. These included 
hot flushes, weight gain, vaginal discharge or dryness, joint 
aches and tiredness, lack of energy, mood swings, and depres-
sion. Women described how these side effects had disrupted 
their day-to-day lives and interactions with others in ways 
they found difficult to manage. Several women spoke about 
deep depression and mood swings, which they originally 
attributed to the stress of diagnosis and active treatment but 
over time associated with AET.
I turned into a monster over the few months following 
chemotherapy. I thought it was the stress of what I had been 
through, but it went on and on. I read on the internet that it 
could be the tamoxifen. I felt depressed and would swing 
into a temper for no reason. [P22 nonadherer]
It [tamoxifen] altered my mind […] I felt almost 
suicidal with it. I didn’t realise it was the drug until I got 
sick and didn’t take it for a week. I felt so much better. 
[P21 nonadherer]
Some side effects were described as frequent, severe, 
and unpredictable, thereby restricting social activities and 
affecting friendships and relationships. This also gave rise 
to a loss of confidence and loss of motivation in life, leading 
to social isolation.
And I didn’t want to go out and I became quite withdrawn 
really, so no, it wasn’t acceptable. [P20 nonadherer]
I didn’t really feel like doing anything. I carried on 
going to work, that was fine. I just couldn’t be bothered 
to do anything out of work – like meet friends, see family. 
I just wanted to vegetate at home. [P24 nonadherer]
In some cases, side effects impacted on the women’s 
confidence to work. One nonadherer described how her 
weight gain and body image had an impact on her role as a 
fitness instructor:
I knew quite a few and people who knew women who had 
put on a lot of weight which they blamed on the tamoxifen 
[…] How am I going to teach [aerobics] when I look like 
a balloon? […] So that was a problem and that was all part 
of the hysteria. [P27 nonadherer]
While women tried to hide their side effects and maintain 
normality, they were also aware that the side effects impacted 
on their partners and friends.
I got thrown into the menopause. […] [O]ne of the things 
that upset me most at the time [was that] I lost all interest 
in sex overnight – it didn’t help my husband as you can 
imagine. [P30 nonadherer]
I talk to my friends but not for very long and not in 
any detail partly because I don’t want [them] to think 
‘I’m not going to bother seeing [name of participant] you 
know.’ – They are only going to go – ‘oh she’s depressed 
or something’. [P31 nonadherer]
Women were often unprepared for side effects. Initial 
information on AET was provided alongside other treatment 
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plans just after diagnosis, but nonadherers struggled to absorb 
information on side effects at this time, as their attention was 
focused on active treatment. As a consequence, they were 
unprepared for the side effects of AETs and the impact on 
their lives.
I am sure I’d been told but you are suddenly bombarded 
with so much information. Not that people mean to do that 
but there is a lot to contend with at a time when you are not 
really taking it in. [P21 nonadherer]
If someone had said to me, these are the side effects 
that other women report – say 20% of women have this 
side effect, and if you get it come back and we can help 
you with it, then that would have been great. It’s a lack of 
information that’s the problem. [P26 nonadherer]
Feeling unsupported
Some nonadherers described “falling through the gaps” in 
the health care system once they had been discharged from 
hospital and were uncertain where to turn for support:
You have the hospital that dealt with the issue and then after 
you have come out of hospital it’s the GP but the GP just 
refers you back to the hospital. So you have that triangle […]
they forget to look at you as a whole person […] They are 
only interested in their own department. [P25 nonadherer]
Many nonadherers appeared unaware that their follow-up 
care had been transferred from the hospital to the GP. There 
was limited contact with their GPs as, despite ongoing pre-
scriptions coming from their primary care practice, most of 
the women ordered their prescriptions online or over the 
phone and collected them from their local pharmacy. In addi-
tion, they were not confident that their GP had appropriate 
expertise regarding their AET and preferred to contact the 
hospital if they had any issues to discuss.
Don’t get me wrong. My GP is lovely. But they don’t know 
much about treatments for breast cancer. I’d rather talk to 
someone at the hospital. [P22 nonadherer]
Similarly, while most described their relationship with 
the breast care nurses (BCNs) as supportive and caring, they 
felt that the BCNs had limited time and had to prioritize 
support for women in having surgery, or on chemotherapy 
or radiation treatment. They therefore hesitated to ask them 
for advice around AET.
The breast care nurses were lovely, but rushed off their feet. 
You didn’t want to disturb them unless it was life or death, if 
you know what I mean. They had a lot of people to see who 
had far greater problems than me. [P23 nonadherer]
Women felt that health professionals were being conser-
vative about what they told them. One woman spoke of how 
the lack of interest and support in how she was dealing with 
side effects had led her to discontinue using the drug.
They are cautious with the amount of information they give 
you. You can tell they are not telling you everything. I can 
understand why they do this, but I would have preferred 
more information. [P31 nonadherer]
They answer questions but very much within their own 
confines. [P27 nonadherer]
I just took myself off it so obviously I felt that nobody 
was interested – I think there needs to be follow-up for 
hormone therapy. [P31 nonadherer]
concerns about long-term AeT use
Nonadherers were often skeptical of the benefits of AET 
and concerned about its toxicity. The following woman, for 
example, felt that there was little to be gained from taking 
the medication long term, once she had been free of cancer 
for 2 years:
I’d taken it for 2 years. I’d given it a go. It’s been two 
years since the breast cancer – I feel back to normal 
now, I don’t think it will make much difference now. 
[P20 nonadherer]
Another had stopped taking AETs because of her concern 
for the way that they had affected her physically.
It scared me what it did to me […] I felt that I was drying up 
from the inside […] I think my vision went slightly blurry 
and I felt older with aches and pains […] dry skin and even 
felt that my teeth were slightly loose. [P29 nonadherer]
For some nonadherers, their general concerns about 
taking any medication long term underpinned their decision 
to discontinue medication.
I just don’t like taking medication – I never take head-
ache tablets I think in the long run they are all harmful. 
[P27 nonadherer]
regaining normality
Most of the nonadherers had stopped taking their medica-
tion 1–2 years after taking it as prescribed. For some, their 
initial nonadherence was not based on a conscious decision 
but happened unintentionally. However, once the precedent 
had been set and the consequences had been perceived as a 
welcome relief from the grind of taking them or the burden 
of side effects, periods of temporary suspension and then a 
permanent discontinuation tended to follow.
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I stopped taking them for a couple of weeks while I was 
on holiday. I’d not taken them before, when I had flu for a 
week, and realised I felt better not taking them. So I wanted 
to enjoy my holiday. Get away from the grind of taking 
them. I just never went back to them. I meant to, it was just 
the longer I didn’t take them […] [P23 nonadherer]
Some women described “wanting to feel better” and not 
wanting to feel “ill” anymore and welcomed the release that 
stopping their medication brought. There was a sense that 
the side effects of the drugs prevented them from getting 
back to normal life.
It just stops you getting on with your life. You have been 
through surgery, then chemotherapy, then you take the 
hormone drugs. You get to the stage when you want to 
get back to normal, but these drugs stop you doing that. 
[P25 nonadherer]
Valuing the quality of life over length of life emerged as 
important for some women. For these women, the importance 
of a good quality of life for their remaining years, with no 
side effects of AET, outweighed the risk of recurrence and 
provided a justification for stopping their medication.
I keep thinking OK – you’re 73 and it’s interesting when 
you are old what it is […] You want to enjoy the life you 
have left. You don’t want to be on medication that makes 
you suffer and then die. [P21 nonadherer]
I think you need to take life by the horns. You make 
that decision and take the consequences. I took the decision 
not to continue because I wanted my normal life again. It is 
about weighing up what is important to you, not the doctor. 
[P26 nonadherer]
risk perception and understanding the risk
Women perceived their risks of recurrence differently. Sev-
eral of the nonadherers believed that they were at low risk 
of the cancer recurring. Statistics was complex, and some 
women found them difficult to understand; there was a mis-
conception around whether they really needed to continue 
with AET.
It’s a difficult one, but I feel it isn’t making that much 
difference to me because I’m low risk anyway. [P28 
nonadherer]
I was Stage 2, so I wasn’t super high risk and I wasn’t 
super low risk – moderate. If I had been higher risk would 
it have changed […] a high risk of it coming back could 
have been different. [P23 nonadherer]
One woman felt that the doctor changed the statistics in 
an effort to persuade her to adhere to AET, causing confusion 
and distrust with the doctor:
I think he said look you are 20% better off on this – you 
are 20% less likely for it to comeback and I questioned it 
a bit – and I said I don’t want to take it – but he said but 
you’re 40% better off when you take it – but I thought of 
saying but you didn’t say that last time – to be fair well 
you know these are statistics – statistics can trick you – you 
can prove anything with statistics – and then when I really 
thought I really don’t want to do this and he went Oh and 
the statistics went the other way – and he said you’re only 
10% better off anyway. [P27 nonadherer]
Discussion
This qualitative study explored factors influencing adherence 
to AET in women with early-stage breast cancer. Factors that 
influenced continued adherence included provision of timely 
expert information about AET, self-efficacy to manage side 
effects, and supportive relationships with health professionals 
and family members. Doing everything possible to reduce the 
risk of recurrence for the sake of family members and fear 
generated from past experience of cancer were also strong 
drivers promoting adherence. Women who had discontinued 
AET described more burdensome side effects, held more 
negative beliefs about the effectiveness of AET, perceived 
continuing AET as a barrier to regaining normality in their 
lives, and placed a greater value on the quality of life over 
quantity of life. In comparison to women who continued with 
treatment, they also seemed to feel less supported by health 
care professionals.
Understanding why people adhere or do not adhere to 
prescribed medication is a complex issue. A recent meta-
analysis of medication adherence in 22 different chronic 
diseases reports that across the range of included studies, 
higher adherence was associated with stronger perceptions of 
necessity of treatment and fewer concerns about treatment.21 
The necessity-concerns framework hypothesizes that if con-
cerns about medication outweigh the perceived necessity of 
taking the medication, then nonadherence is likely, and if the 
perceived necessity to take the medication outweighs the con-
cerns, adherence is likely.22 This framework has previously 
been used to assess the beliefs and perceptions of treatment 
for breast cancer23–25 and other cancers.26,27 Women in our 
study often appeared to weigh up their beliefs about AET 
and their fears of recurrence alongside their experiences of 
the treatment and its impact on their daily lives to inform 
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whether they adhere or not, and thus our findings fit well 
with this theoretical framework.
Our findings are consistent with and add depth to previ-
ous quantitative studies, including our own, which have 
addressed this topic.14,15 There have been only two previous 
qualitative studies conducted in this area.17,18 Harrow et al’s17 
study focused mainly on the experiences of women who 
were adherers to AET. The burden of side effects was 
reported, and the study concluded that the advice, support, 
and monitoring needed for adherence are not routinely 
offered in conventional follow-up settings. Cahir et al18 
interviewed both adherers and nonadherers in Ireland. This 
study identified modifiable influences on hormonal therapy 
medication taking behavior including barriers and enablers 
to AET across the following three strata: beliefs about conse-
quences, medication use, intentions and goals, and behavior 
regulation. Our findings are consistent with, and add weight 
to, the findings from these two studies.
Nonadherers in our study reported that a desire to feel 
“normal” again led to discontinuation with AET. A previous 
study found that while 90% of women adhered to AET in 
the first year, this figure dropped to 50% by the fifth year.11 
Nonadherence may therefore coincide with a false sense 
of security of being “better” or a sense of returning to nor-
mality over time that may tip the balance of the necessity-
concerns framework described by Horne et al,22 leading to 
nonadherence. It may also coincide with declining belief 
in the efficacy of hormonal therapy; this is consistent with 
findings from previous quantitative studies, which found that 
negative beliefs in the effectiveness of AET can influence 
nonadherence.14,15 Studies report that in chronic diseases, 
prioritization of the importance of medication intake declines 
over time combined with issues of medication being seen 
as a reminder of the patients’ condition at a time when they 
are feeling well again and ongoing medication makes the 
person feel old or bad about themselves.28 As this study 
reports, permanent discontinuation often follows an unin-
tentional period of temporary suspension, such as illness 
and forgetting to take tablets away with them. The feeling 
of normality during the temporary suspension can lead to 
intentional discontinuation.
Our findings have a number of implications for practice 
(refer Box 10). First, it is important that women receive 
timely information and discussion about AET in order to 
understand the benefits of taking AET as prescribed to 
ensure that they are adequately prepared for side effects 
that may occur and that they are equipped with coping 
strategies and information on where to seek support either 
through professional channels or other forms of support. The 
importance of well-timed information within the cancer tra-
jectory has been widely recognized as important.29–31 A lack 
of adequate preparation for the impact of side effects has 
been shown to have a negative psychological response to 
cancer treatments. Where patients receive good preparation 
and education from health professionals, this empowers and 
enables them to cope better.32
Providing clear explanations of benefits and risks associ-
ated with taking and not taking AET is also important.33 This 
is often not clearly communicated by health professionals. 
The challenge is to continue trying to improve risk com-
munication in health care, turning data into something more 
meaningful, relevant, and useful for individual patients. This 
could be achieved by adopting simple and practical strategies 
such as decision aids, tailored information, and consultation 
summaries informed by the best available evidence base.34
It is important for women to be able to discuss the poten-
tial difficulties of remaining adherent with long-term therapy 
and for health professionals to provide information and instill 
confidence in long-term management of hormone therapy.35 
Health professionals should follow a patient-centered 
approach to care that promotes active patient involvement 
in management and coping strategies around AET, which in 
turn empowers women to take the control of their medication 
regime.36 Problem-solving techniques or cognitive behav-
ioral techniques have potential to overcome the barriers to 
adherence and may improve communication channels with 
health professionals.37 Increased communication and trust 
with the doctor–patient relationship increase willingness 
to accept medical advice and adherence to long-term pre-
ventative regimens such as AET.38–41 Studies show that the 
majority of patients still prefer to interact with health care 
professionals rather than gain information online or receive 
a booklet.34,42 In this study, women suggested the need for 
follow-up specific to AET to provide support, reassurance, 
and prompt discussion of any issues arising.
Our findings also suggest that possible avenues for sup-
port for women concerned about AET were poorly signposted 
and women were unclear about whom they should contact. 
Specialist BCNs are a point of contact for these women, but 
once discharged, women no longer perceive it as the nurse’s 
role. Long-term follow-up is with the GP, and thus, GPs have 
a potentially important role to play, especially as the length of 
hospital follow-up decreases and the recommended duration 
of AET increases. While adherers in our study were generally 
quite positive about the GP relationship, nonadherers were 
more ambivalent and critical of their specific knowledge. 
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This highlights the importance of ensuring that GPs are 
educated regarding the issues experienced by women taking 
AET so they can provide more accurate information and sup-
port and encourage adherence. Even following a period of 
nonadherence, GPs could have an important role in helping 
women understand that restarting may still be beneficial.43 
Alternatively, novel pathways could be explored, such as a 
nurse-led discharge intervention, a primary care nurse cancer 
care review, and a community pharmacist-led intervention.
strengths and limitations
The qualitative methods of inquiry used in this study pro-
vided richer and more detailed information about adherence 
behaviors and opportunities and interventions to improve 
adherence to AET. The inclusion of a sample of nonadherers 
as well as adherers is a particular strength. Although our par-
ticipants varied in terms of socio-demographic characteristics 
and presented a range of views, we were not able to recruit 
younger nonadherent women and the adherers therefore had 
a greater age range. Furthermore, we were not able to recruit 
from the black and minority ethnic groups. It should also be 
noted that a large proportion of women in our sample were 
on tamoxifen and that the experiences of women on AIs 
may be different and under-represented in our sample. For 
example, joint pain is a recognized side effect of AIs, which 
was not reported by women in our study. Furthermore, as 
with all qualitative studies, the small sample size and the 
purposive sampling strategy mean that the results may not 
be generalizable to a wider population. However, qualitative 
study designs provide depth and insight, identify nuances 
that may not have been identified through other methods, 
help inform the acceptability, and provide patient-centered 
approaches to the developing interventions.
Conclusion
Improving adherence to AET will reduce recurrence of and 
mortality from breast cancer. However, medication-taking 
behavior is complex and involves patient, health profes-
sional, and process components. Medication adherence is not 
exclusively the responsibility of the patient. This qualitative 
study has provided an in-depth description of factors, which 
can influence adherence to AET, and points to interventions 
that could assist in improving adherence. These include the 
provision of timely information on the efficacy of AET, 
preparing expectations around side effects, and providing 
information and support on how to manage burdensome side 
effects. Good communication and trust between the health 
professionals and the patient are important. Doctors should 
follow a patient-centered approach to care that promotes 
active patient involvement in the decision-making process 
around AET. Training and education around AET for GPs 
should be considered, and novel care pathways to help 
manage the medication, such as primary care nurse cancer 
care review and community pharmacist follow-up, should 
be explored.
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